Neochem FY26: scale-up execution lifts margins while working capital stretches

Neochem Bio Solutions Limited closed FY26 with a sharper operating profile and a clearer growth story than it had two years ago. Revenue from operations rose to ₹110.7 crore in FY26, up 32 percent year on year from ₹84.2 crore in FY25. The profit engine improved faster than topline. EBITDA increased to ₹22.6 crore and PAT climbed to ₹12.0 crore. That translated into an EBITDA margin of 20.4 percent and a PAT margin of 10.6 percent for FY26.

This FY26 earnings update matters because it shows how Neochem is using its manufacturing flexibility and formulation depth to move from volume growth to profit-led growth. It also flags a trade-off investors should track closely: a sharp rise in receivables and a longer cash conversion cycle, even as leverage has fallen.

A specialty chemical platform built around formulations, not commodities

Neochem manufactures specialty performance chemicals across four core product platforms: polymers, surfactants, silicones, and ester and bio-based solutions. These chemistries serve end markets that range from textile and garment processing to home and personal care, institutional and industrial cleaners, water treatment, paints and coatings, paper and pulp, construction and rubber, and dyes and pigments.

The company’s operating design is built for customization. It highlights more than 350 customized formulations, supported by in-house R&D and application labs. It also reports 40 registered trademarks. This matters in specialty chemicals because customer stickiness often follows application-specific performance, repeatability, and compliance.

The production backbone is an ISO-certified manufacturing unit in Moraiya, Ahmedabad with installed capacity of 22,000 MTPA. Neochem can handle both liquid and powder chemistries and runs flexible batch manufacturing across polymers, surfactants, silicones, and bio-based formulations. The process is structured around controlled steps from raw material charging and reactor heating to in-process testing, discharge, packaging, and final quality checks.

Capacity utilization has been trending up for four years. Production rose from 5,414 MT in FY23 to 11,589 MT in FY26. Utilization moved from 24.6 percent to 52.7 percent over the same period. The company is still operating with headroom, which supports growth without immediate large capex, but it also raises the bar on execution: consistent quality, faster changeovers, and supply reliability become more important as throughput climbs.

Neochem’s quality and sustainability positioning is also central to its customer acceptance, particularly in textiles and export-linked supply chains. It lists certifications including ISO 9001, ISO 14001, ISO 45001, ZDHC Level 3, and GOTS 7.0. The company also states it operates with zero liquid discharge and an in-house ETP.

FY26 financials: margins expand faster than revenue

The FY26 headline numbers show improving operating leverage. Revenue grew 32 percent year on year, but EBITDA grew 53 percent and PAT grew 62 percent.

The expansion is visible in the margin bridge over two years. EBITDA margin rose from 11.0 percent in FY24 to 20.4 percent in FY26. PAT margin rose from 2.7 percent to 10.6 percent over the same period. Gross profit margin, however, declined from 34.2 percent in FY24 to 31.0 percent in FY26. That combination suggests that the company’s cost structure below gross profit improved meaningfully, even while material costs and mix kept gross margin under pressure.

In H2 FY26, revenue from operations was ₹64.9 crore versus ₹47.2 crore in H2 FY25. H2 FY26 EBITDA was ₹12.6 crore versus ₹9.6 crore, with EBITDA margin largely stable at 19.4 percent compared with 19.6 percent. PAT in H2 FY26 was ₹6.9 crore versus ₹5.5 crore.

A key balance sheet change in FY26 is the sharp improvement in leverage. Net debt to equity moved from 1.7 in FY25 to 0.2 in FY26. Shareholders’ equity increased to ₹78.8 crore in FY26 from ₹19.8 crore in FY25, with share capital rising from ₹6.7 crore to ₹17.1 crore and reserves rising to ₹61.7 crore. Borrowings also declined, with non-current borrowings falling to ₹0.7 crore.

Returns are still elevated even after normalizing from the very high FY25 base. ROCE is 36.8 percent in FY26 versus 40.9 percent in FY25 and 21.3 percent in FY24. ROE is 24.4 percent in FY26.

Working capital is the main FY26 pressure point

The most important caution signal in this presentation is not on the P&L. It is in working capital.

Trade receivables increased materially to ₹48.7 crore in FY26 from ₹25.3 crore in FY25. Debtor days rose to 122 in FY26 from 92 in FY25. Inventory days improved slightly to 127 from 134, but that was not enough to offset the receivables stretch. The cash conversion cycle expanded to 181 days in FY26 from 128 days in FY25.

This shows up in cash flows. Net cash from operating activities was negative ₹19.1 crore in FY26, compared with positive ₹2.5 crore in FY25. Investing cash flow was negative ₹6.5 crore. Financing cash flow was positive ₹25.7 crore, which helped keep net cash broadly stable.

For investors, this is the operational question to monitor in FY27: whether the faster growth is being funded by customers through longer credit, and if the company can bring receivables back in line without slowing demand. The company’s distribution-led model, with 50+ authorized distributors and 225+ domestic customers, can support reach, but it also requires tight credit discipline. Neochem states it serves 200+ domestic customers annually, which implies a broad base, but the receivables jump suggests either higher sales concentration, longer terms, or timing issues that should be watched.

Strategy and market context: India’s specialty chemical tailwinds, plus diversification

Neochem’s growth narrative sits inside a wider industry tailwind. The presentation points to structural drivers for India’s specialty chemical opportunity: China+1 supply chain shifts, import substitution, and sustainability-led demand. It also highlights diversified end-market demand as a stabilizer.

In textiles, where Indian chemical consumption is rising with premiumization and sustainability compliance, the presentation cites a domestic textile chemicals market projected to expand from ₹0.30 lakh crore in FY25E to ₹0.50 lakh crore by FY29P. For the broader domestic specialty chemicals market, it cites growth from ₹5.00 lakh crore in FY25E to ₹7.50 lakh crore in FY29P.

Against that backdrop, Neochem’s strategy is built around two ideas: widen end-use exposure and lead with performance and compliance.

First, diversification. The company is expanding beyond its traditional textile base into home and personal care, industrial and institutional cleaning, water treatment, and construction-linked chemistries. It notes that home and personal care contribution scaled from 2.18 percent in FY23 to 10.30 percent in FY25 and reached 14.21 percent by September 2025, indicating reduced dependence on textiles.

Second, product and process innovation. Neochem positions its R&D around process efficiency, sustainable and bio-based chemistries, and application-led partnerships. It calls out initiatives such as vegan softeners replacing tallow-based conditioners, phosphate-free sequestering and chelating agents, clay-based scouring agents, and corn-glucose surfactants. The commercial logic is simple: if customers can save water, energy, and time while meeting standards like ZDHC and GOTS, then switching costs rise and price sensitivity falls.

The presentation includes examples of this approach. In polymers, it developed a polymer blend to replace a high-cost detergent raw material, marketed as Ampinol Max, positioned around anti-redeposition and dispersion benefits. In surfactants, it developed Ampinol RDP as a single-bath washing-off agent to replace a two-bath system, positioned around water, energy, and time savings. In ester and bio-based solutions, it developed vegan ester quats from palm and soya fatty acids to replace animal-fat conditioners.

Partnerships add another lever. Neochem states it has exclusive rights in India, Bangladesh, and Sri Lanka, starting July 2024, to a Netherlands partner’s fluorine-free, bio-based water and stain repellents for textiles and construction. This aligns with the company’s stated goal of entering higher value, regulation-driven niches.

What the FY26 update suggests about the next phase

Neochem’s FY26 story is one of scaling with improving profitability. A four-year increase in capacity utilization, a broader product footprint, and strong certification credentials support this trajectory. The financial results reinforce that the model is currently delivering operating leverage, with EBITDA and PAT outpacing revenue growth.

The balancing item is cash discipline. FY26 shows that growth has pulled receivables and the cash conversion cycle higher, driving negative operating cash flow. The company has reduced leverage significantly, which gives flexibility, but sustained compounding will still depend on converting accounting profits into cash.

If Neochem can protect margins while normalizing debtor days, the platform looks positioned for a steadier quality of earnings. The management team’s stated focus on process innovation, sustainable chemistries, and diversification across end markets sets a sensible agenda. The next set of investor checks should be straightforward: receivables trend, export traction beyond the current 5 percent share, and whether capacity utilization continues to rise without compromising batch consistency and compliance.

In FY26, the theme is disciplined scale-up. Neochem is growing faster, earning more per rupee of sales, and building a wider product moat through application-led chemistry. Now it needs to show that this growth can also be cash-efficient.